Search results
Results From The WOW.Com Content Network
The term variant of concern (VOC) for SARS-CoV-2, which causes COVID-19, is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity (e.g., N501Y) in RBD-hACE2 complex (genetic data), while also being linked to rapid spread in human populations ...
SARS-CoV-2 is the seventh known coronavirus to infect people, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. [105] Like the SARS-related coronavirus implicated in the 2003 SARS outbreak, SARS‑CoV‑2 is a member of the subgenus Sarbecovirus (beta-CoV lineage B). [106] [107] Coronaviruses undergo frequent recombination. [108]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The continued spread of the SARS-CoV-2 virus has spawned a Greek alphabet of variants - a naming system used by the World Health Organization to track concerning new mutations of the virus that ...
Theta variant, also known as lineage P.3, [a] is one of the variants of SARS-CoV-2, the virus that causes COVID-19. The variant was first identified in the Philippines on February 18, 2021, when two mutations of concern were detected in Central Visayas . [ 1 ]
The Gamma variant (P.1) [a] was [6] [7] one of the variants of SARS-CoV-2, the virus that causes COVID-19. [8] This variant of SARS-CoV-2 has been named lineage P.1 and has 17 amino acid substitutions , ten of which in its spike protein, including these three designated to be of particular concern: N501Y , E484K and K417T.
COVID-19 pandemic, a coronavirus pandemic that began in December 2019 and ended in May 2023; Variants of SARS-CoV-2. SARS-CoV-2 Alpha variant, a variant of SARS-CoV-2 first identified in the United Kingdom in 2020; SARS-CoV-2 Beta variant, a variant of SARS-CoV-2 first identified in South Africa in 2020
The most recent COVID-19 vaccine should offer protection against the XEC variant, Russo says. “The most recent version of the vaccine seems to be reasonably well-matched,” he says.